PARP inhibitors may have clinical utility in HER2-positive breast cancers
Poly (ADP-Ribose) polymerase (PARP) inhibitors, shown to have clinical activity when used alone in women with familial breast and ovarian cancers linked to BRCA mutations, may be a novel treatment strategy in women with HER2-positive ...
Sep 17, 2012
0
0